Search - tctmd.com

Displaying 141 - 153 of 153

Sort: Relevancy | Date

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

April 29, 2015

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

News Daily News

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

July 24, 2013

News Daily News

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

July 24, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

L.A. McKeown

August 09, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Daily News

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Jason Kahn

February 09, 2011

Advertisement

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content